MUC1 Immunotherapy

Richard Beatson; Joy Burchell; Joyce Taylor-Papadimitriou

doi:10.2217/imt.10.17

MUC1 Immunotherapy

Richard Beatson, Joy Burchell, Joyce Taylor-Papadimitriou

Comprehensive Cancer Centre

Research output: Contribution to journal › Article › peer-review

121 Citations (Scopus)

Abstract

The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.

Original language	English
Pages (from-to)	305-327
Number of pages	23
Journal	Immunotherapy
Volume	2
Issue number	3
DOIs	https://doi.org/10.2217/imt.10.17
Publication status	Published - May 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt.10.17

Cite this

@article{b754c7240dd54705b7ad94dcd10c5b02,

title = "MUC1 Immunotherapy",

abstract = "The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.",

author = "Richard Beatson and Joy Burchell and Joyce Taylor-Papadimitriou",

year = "2010",

month = may,

doi = "10.2217/imt.10.17",

language = "English",

volume = "2",

pages = "305--327",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - MUC1 Immunotherapy

AU - Beatson, Richard

AU - Burchell, Joy

AU - Taylor-Papadimitriou, Joyce

PY - 2010/5

Y1 - 2010/5

N2 - The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.

AB - The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.

U2 - 10.2217/imt.10.17

DO - 10.2217/imt.10.17

M3 - Article

SN - 1750-743X

VL - 2

SP - 305

EP - 327

JO - Immunotherapy

JF - Immunotherapy

IS - 3

ER -